net dbt
oper headwind remain
macro headwind add risk oper uncertainti
continu struggl oper across segment
macro uncertainti creat potenti pressur calendar
pharmaceut segment brand inflat guidanc mid-singl digit establish
moder view vs histor level on-going discuss around futur
pbm rebat creat addit uncertainti constrain margin get
januari price increas cycl addit commentari around
gener program headwind somewhat contradict commentari around market
stabil leav anoth element growth rebound lack certainti meanwhil
medic write-down cordi quarter exampl on-going pressur
part busi think like persist near-term risk
limit upsid visibl ahead januari brand price increas reiter
ep oper headwind segment
follow earn reduc ep
ep reduc oper outlook account
continu pharma margin headwind includ drug price question well
on-going uncertainti pathway forward rebound core medic growth
off-set somewhat lower tax rate assumpt although fulli offset
reduct maintain price object equat
upcom event catalyst
next catalyst like macro-ori includ updat
depart human servic hh propos remov
current safe harbor rebat pbm plan sponsor would follow-on
impact drug distributor would creat uncertainti price
pathway move forward addit announc brand
manufactur current futur price hike could impact share
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest drug medic product
two-third profit pharmaceut
busi nearli one-third medic
support retail/mail/hospital/physician client
well drug manufactur medic busi
manufactur portfolio medic
product distribut brand-nam product
hospit physician compani base
under-perform rate driven increasingli
competit market compani core
busi pharmaceut medic devic
limit near-term offset think market
pharmaceut distribut remain
challeng near term histor upsid driver
red oak sourc benefit slow
medic cordi platform like support
solid growth ex-u see price volum
non-gaap ep came higher expect due lower tax rate
revenu growth exist new custom
red oak posit impact gener program headwind
expect pd grow oper earn
exit mani tsa exit addit tsa later earli
path profit growth end
sold interest busi
busi mix balanc
divest chines distribut busi would requir futur
annual cost save signific reduct
workforc larg complet
invest save busi
reinvest busi return valu sharehold
 near-term limit focus
contribut drove higher sg continu
effect tax rate quarter driven one-tim tax benefit
restructur intern busi faster
anticip progress put posit benefit tax
reform
goodwil impair charg annual impair test
primarili relat cordi
expect drive annual save cost
reduct initi drive addit save
aggreg run rate excess
expect accret in-lin prior accret target
impact loss pharmerica
brand inflat estim mid-singl digit
gener sell-sid deflat similar last year
red oak strong less
gain gener
feel good red oak less posit prior year
fewer gener launch year
gener volum grow
brand inflat assumpt mid-singl digit assumpt assum
decemb second half year
less brand dsa impact inflat
activ convers manufactur conting
portion continu look de-risk
juli typic second import month far distant second
littl light brand manufactur may wait
end calendar year still expect strongest
forecast brand inflat slightli less
expect inflat come
brand inflat percentag point expect
abl absorb zero could creat sort
beyond return growth distribut
custom price renew
expect custom renew headwind
renew alreadi occur
one custom optum went three year
contract six year contract
segment result medic compens relat underli
larg corpor expens relat contribut
medic
margin expect see given
non-recur natur question
rank order headwind guidanc
growth exist busi specialti doubl digit
tax rang
discretionari contribut expect
net benefit cost structur initi expect annual
save reinvest larg portion back
divestitur china navihealth
last temper brand inflat
convers brand manufactur willing chang
get paid
contract conting last year
move non-conting year
expect littl lower brand inflat rate
chang wac price occur brand manufactur understand
glove busi resolv
situat differ past sever quarter
lap effect increas cost
began see
work address cost concern
dont see headwind tri implement
initi improv cost posit
price object ep multipl five-year
averag discount incorpor margin price pressur
pharmaceut segment slow brand inflat increas competit
downstream independ buy group discount medic segment
incorpor grow risk non-tradit distributor
upsid risk po potenti volum pickup increas buyside/sellsid
spread faster-than-expect contribut recent acquir medic
busi capit deploy downsid risk po increment wors
drug price pressur increas competit creat gross profit headwind risk
amazon anoth disrupt forc enter suppli chain market lack
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
